Liver X receptors agonist T0901317 promotes human umbilical vein endothelial cell proliferation via activation of PI3K/Akt pathway

王强; 余洁; 王航; 卢巍; 邓梦杨; 康华利; 黄岚

您当前的位置：

首页 >

文章列表页 >

Liver X receptors agonist T0901317 promotes human umbilical vein endothelial cell proliferation via activation of PI3K/Akt pathway

更新时间：2026-01-09

- Liver X receptors agonist T0901317 promotes human umbilical vein endothelial cell proliferation via activation of PI3K/Akt pathway
- Journal of Army Medical University Vol. 34, Issue 6, Pages: 481-484(2012)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R322.123;R329.26;R341
- Published：2012
- 稿件说明：
移动端阅览
王强,余洁,王航,卢巍,邓梦杨,康华利,黄岚.LXRs激动剂T0901317通过PI3K/Akt增强人脐静脉内皮细胞的增殖能力[J].陆军军医大学学报(原第三军医大学学报),2012,34(06):481-484.

　Wang Qiang,Yu Jie,Wang Hang,Lu Wei,Deng Mengyang,Kang Huali,Huang Lan.Liver X receptors agonist T0901317 promotes human umbilical vein endothelial cell proliferation via activation of PI3K/Akt pathway[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(06):481-484.
王强,余洁,王航,卢巍,邓梦杨,康华利,黄岚.LXRs激动剂T0901317通过PI3K/Akt增强人脐静脉内皮细胞的增殖能力[J].陆军军医大学学报(原第三军医大学学报),2012,34(06):481-484. DOI：

　Wang Qiang,Yu Jie,Wang Hang,Lu Wei,Deng Mengyang,Kang Huali,Huang Lan.Liver X receptors agonist T0901317 promotes human umbilical vein endothelial cell proliferation via activation of PI3K/Akt pathway[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(06):481-484. DOI：

摘要

目的观察肝X受体（liver X receptors，LXRs）激动剂T0901317对人脐静脉内皮细胞（human umbilical vein endothelial cell，HUVEC）增殖活性的影响。方法体外分离和培养原代HUVEC，不同浓度的T0901317（0、0.5、2、5 μmol/L）干预HUVEC 48 h后，采用MTS法检测HUVEC增殖情况；Western blot检测磷酸化Akt（Ser

473

）及总Akt的表达。结果 T0901317（0~5 μmol/L）呈浓度依赖性的促进HUVEC的增殖（P0.01）和上调HUVEC中p-Akt-Ser

473

的表达（P0.01），PI3K抑制剂LY294002（10 μmol/L）和基因转录抑制剂放线菌素-D（actinomycin D，Act-D，5 μg/ml）可以阻断T0901317（5 μmol/L）上调p-Akt-Ser

473

的作用（P0.01），提示T0901317通过基因转录调节的方式激活PI3K/Akt信号，此外，PI3K抑制剂LY294002（10 μmol/L）预处理可以逆转T0901317（5 μmol/L）促HUVEC增殖作用（P0.01）。结论 LXRs激动剂T0901317可通过激活PI3K/Akt信号通路增强HUVEC的增殖能力。

Abstract

Objective To observe the effect of liver X receptors (LXRs) agonist T0901317 on human umbilical vein endothelial cells (HUVECs) proliferation. Methods The HUVECs isolated and cultured in vitro were treated with different concentrations of T0901317 (0

0.5

2 and 5 μmol/L) for 48 h. The proliferation of HUVECs was evaluated by MTS assay. The expressions of phospho-Akt (Ser

473

) and total Akt were detected by Western blotting. Results The HUVEC proliferation was significantly promoted and the phospho-Akt (Ser

473

) expression was significantly upregulated by T0901317 in a dose-dependent manner (P0.01). The upregulation of phospho-Akt (Ser

473

) induced by T0901317 could be blocked by PI3K inhibitor LY294002 (10 μmol/L) and gene transcription inhibitor actinomycin D (Act-D) (5 μg/ml) (P0.01)

indicating T0901317 activated PI3K/Akt pathway through regulating gene transcription. Moreover

pretreatment of HUVECs with LY294002 (10 μmol/L) could reverse T0901317-induced HUVEC proliferation (P0.01). Conclusion The LXRs agonist T0901317 can promote HUVEC proliferation through the activation of PI3K/Akt pathway.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Role of miRNA-142-5p in regulation of rat corneal neovascularization and related pathways

Promoting effect of ultra-low dose DMSO on fibroblast proliferation and its underlying mechanism

GPX7 regulates proliferation and senescence of hepatocellular carcinoma cells through the PI3K-AKT pathway

Mechanism of abnormal specification of spermatogonial stem cells after Rb1 knockout in mitotic-arrested prospermatogonia

Related Author

李化

李彦

周善璧

TAN Ranjing

KANG Tehao

WU Dengyan

WANG Ruiguan

WANG Jing

Related Institution

Center for Dermatology and Medical Cosmetology， the Second Affiliated Hospital of Chongqing Medical University

Department of Dermatology， Plastic and Cosmetic Surgery， Wushan People’s Hospital

Faculty of Hepatobiliary and Pancreatic Surgery， First Medical Center， General Hospital of PLA， Beijing, Air Force Medical Center of PLA

Department of Hepatobiliary Surgery， Eighth Medical Center， General Hospital of PLA， Beijing, Air Force Medical Center of PLA

Department of Radiation Oncology, Air Force Medical Center of PLA

⁰